Skip Navigation



European Heart Journal Advance Access published online on December 21, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm535
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/2/150    most recent
ehm535v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gornik, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gornik, H. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Peripheral arterial disease enters the biomarker era. Does risk stratification tell us something that we don't already know?

Heather L. Gornik*

Department of CV Medicine, Cleveland Clinic, 9500 Euclid Avenue–Desk S60, Cleveland, OH 44195, USA

* Corresponding author. Tel: +1 216 445 3689, Fax: +1 216 444 7370, Email: gornikh@ccf.org

This editorial refers to ‘Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease’ by G. Brevetti et al., doi:10.1093/eurheartj/ehm587

The first 10% of the full text of this article appears below.

After decades of obscurity, peripheral arterial disease (PAD) is gaining recognition as a serious cardiovascular (CV) disorder. It is estimated that >27 million individuals in Europe and the USA have PAD, though there remains a widespread lack of awareness of this disorder among at-risk patients and healthcare professionals.1,2 In addition to functional impairment and related effects on quality of life, individuals with PAD are at a markedly increased risk of a major CV event, namely myocardial infarction (MI), stroke, and death.

Brevetti and colleagues have investigated the utility of two inflammatory biomarkers, high sensitivity C-reactive protein (hs-CRP) and myeloperoxidase (MPO), to stratify CV risk among patients with PAD.3 A cohort of 156 patients with intermittent claudication and an ankle–brachial index (ABI) . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease
Gregorio Brevetti, Vittorio Schiano, Eugenio Laurenzano, Giuseppe Giugliano, Mario Petretta, Francesco Scopacasa, and Massimo Chiariello
EHJ 2008 29: 224-230. [Abstract] [FREE Full Text]